• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年人伴或不伴糖尿病患者强化与标准血压控制的比较:一项随机对照试验的系统评价和荟萃分析。

Intensive versus standard blood pressure control in older persons with or without diabetes: a systematic review and meta-analysis of randomised controlled trials.

机构信息

Diabetes Research Centre, College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester, LE5 4PW, UK.

NIHR Applied Research Collaboration - East Midlands, Leicester, LE5 4PW, UK.

出版信息

J R Soc Med. 2023 Apr;116(4):133-143. doi: 10.1177/01410768231156997. Epub 2023 Feb 24.

DOI:10.1177/01410768231156997
PMID:36825537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10164272/
Abstract

OBJECTIVES

To assess and compare the benefits and harms of intensive versus standard blood pressure (BP) control in older people with or without diabetes mellitus (DM).

DESIGN

Systematic review and meta-analysis.

SETTING

Randomised controlled trials comparing intensive versus standard BP control, identified from MEDLINE, Embase, The Cochrane library, Web of Science and a search of bibliographies from inception till August 2022.

PARTICIPANTS

Older people (≥65 years) with or without DM.

MAIN OUTCOME MEASURES

Study-specific risk ratios (RRs) with 95% confidence intervals (CIs) were pooled for adverse vascular and safety outcomes.

RESULTS

We included six randomised controlled trials (RCTs) comprising 20,985 patients (intensive BP = 10,474 and standard BP = 10,511) with a weighted mean follow-up of 3.1 years. In the general population, the RRs (95% CIs) of intensive versus standard BP control for composite cardiovascular events or major adverse cardiovascular events (CVD/MACE), CVD mortality, coronary heart disease, stroke and heart failure were 0.71 (0.62-0.82), 0.65 (0.49-0.86), 0.75 (0.60-0.95), 0.75 (0.61-0.92) and 0.58 (0.41-0.82), respectively. Intensive BP control did not increase the risk of renal failure or serious adverse events in the general population. Two RCTs reported results for composite CVD/MACE in patients with DM with a pooled estimate of 0.85 (0.67-1.07).

CONCLUSIONS

Aggregate trial evidence shows that intensive BP control (<120 to <140 mmHg) reduces the risk of adverse cardiovascular outcomes in older hypertensive patients in the general population with no increase in adverse events. Intensive BP control may confer similar benefits for older patients with DM with no evidence for harm, but this is based on limited data.PROSPERO Registration: CRD42022349791.

摘要

目的

评估和比较强化与标准血压(BP)控制对有或无糖尿病(DM)的老年人的益处和危害。

设计

系统评价和荟萃分析。

设置

从 MEDLINE、Embase、The Cochrane 图书馆、Web of Science 和 2022 年 8 月为止的文献目录中检索比较强化与标准 BP 控制的随机对照试验。

参与者

有或无 DM 的老年人(≥65 岁)。

主要观察结果

针对不良血管和安全性结局,汇总了研究特异性风险比(RR)及其 95%置信区间(CI)。

结果

我们纳入了 6 项随机对照试验(RCT),共纳入 20985 例患者(强化 BP=10474 例,标准 BP=10511 例),加权平均随访时间为 3.1 年。在一般人群中,强化 BP 与标准 BP 控制相比,复合心血管事件或主要心血管不良事件(CVD/MACE)、CVD 死亡率、冠心病、卒中和心力衰竭的 RR(95%CI)分别为 0.71(0.62-0.82)、0.65(0.49-0.86)、0.75(0.60-0.95)、0.75(0.61-0.92)和 0.58(0.41-0.82)。强化 BP 控制并未增加一般人群中肾衰竭或严重不良事件的风险。两项 RCT 报告了糖尿病患者复合 CVD/MACE 的结果,汇总估计值为 0.85(0.67-1.07)。

结论

综合试验证据表明,强化 BP 控制(<120 至 <140mmHg)可降低一般人群中高血压老年患者不良心血管结局的风险,且不会增加不良事件。强化 BP 控制可能对无不良事件证据的糖尿病老年患者带来类似的益处,但这基于有限的数据。

PROSPERO 注册:CRD42022349791。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/82f6b7940e8c/10.1177_01410768231156997-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/85a36e8609ff/10.1177_01410768231156997-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/7b628cdcd14f/10.1177_01410768231156997-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/19602982dd3d/10.1177_01410768231156997-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/a932c5a5429a/10.1177_01410768231156997-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/82f6b7940e8c/10.1177_01410768231156997-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/85a36e8609ff/10.1177_01410768231156997-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/7b628cdcd14f/10.1177_01410768231156997-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/19602982dd3d/10.1177_01410768231156997-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/a932c5a5429a/10.1177_01410768231156997-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/335e/10164272/82f6b7940e8c/10.1177_01410768231156997-fig5.jpg

相似文献

1
Intensive versus standard blood pressure control in older persons with or without diabetes: a systematic review and meta-analysis of randomised controlled trials.老年人伴或不伴糖尿病患者强化与标准血压控制的比较:一项随机对照试验的系统评价和荟萃分析。
J R Soc Med. 2023 Apr;116(4):133-143. doi: 10.1177/01410768231156997. Epub 2023 Feb 24.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Blood pressure targets in adults with hypertension.高血压成人的血压目标。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3.
4
Associations of blood pressure with cardiovascular and mortality outcomes in over 2 million older persons with or without diabetes mellitus: A systematic review and meta-analysis of 45 cohort studies.200多万患有或未患有糖尿病的老年人中血压与心血管及死亡结局的关联:45项队列研究的系统评价和荟萃分析
Prim Care Diabetes. 2023 Dec;17(6):554-567. doi: 10.1016/j.pcd.2023.09.007. Epub 2023 Oct 6.
5
Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients.老年高血压患者强化降压治疗的结局。
J Am Coll Cardiol. 2017 Feb 7;69(5):486-493. doi: 10.1016/j.jacc.2016.10.077.
6
Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis.勃起功能障碍、磷酸二酯酶-5抑制剂的使用与糖尿病患者的心血管疾病风险及死亡率:一项系统评价和荟萃分析。
Prim Care Diabetes. 2022 Oct;16(5):601-613. doi: 10.1016/j.pcd.2022.09.004. Epub 2022 Sep 14.
7
Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.强化血压治疗的益处与危害:利用收缩压干预试验(SPRINT)和控制糖尿病患者心血管风险行动(ACCORD)试验数据推导和验证风险模型
PLoS Med. 2017 Oct 17;14(10):e1002410. doi: 10.1371/journal.pmed.1002410. eCollection 2017 Oct.
8
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.强化降压对心血管和肾脏结局的影响:更新的系统评价和荟萃分析。
Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Epub 2015 Nov 7.
9
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.高血压和心血管疾病患者治疗的血压目标
Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. doi: 10.1002/14651858.CD010315.pub4.
10
Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.降糖治疗对糖尿病患者结局发生率的影响以及血压和其他临床变量的调节作用:概述、随机试验的荟萃分析。
J Hypertens. 2019 Oct;37(10):1939-1949. doi: 10.1097/HJH.0000000000002152.

引用本文的文献

1
Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation.强化降压治疗目标有效性的系统评价:巴西心脏病学会(SBC)建议
Arq Bras Cardiol. 2025 Mar;122(3):e20240761. doi: 10.36660/abc.20240761.
2
Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽 1 受体激动剂对心血管和肾脏结局影响的种族、民族和地域差异:心血管结局试验的系统评价和荟萃分析。
J R Soc Med. 2024 Aug;117(8):267-283. doi: 10.1177/01410768231198442. Epub 2023 Sep 21.
3

本文引用的文献

1
Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂 (SGLT2-I) 和肾素-血管紧张素-醛固酮系统抑制剂 (RAAS-I) 与 SGLT2-I 单独用于 2 型糖尿病患者的获益和危害:一项随机对照试验的系统评价和荟萃分析。
Endocrinol Diabetes Metab. 2022 Jan;5(1):e00303. doi: 10.1002/edm2.303. Epub 2021 Oct 12.
2
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.老年高血压患者强化血压控制试验。
N Engl J Med. 2021 Sep 30;385(14):1268-1279. doi: 10.1056/NEJMoa2111437. Epub 2021 Aug 30.
3
A diabetes update.糖尿病最新情况
J Diabetes. 2023 Jul;15(7):542-544. doi: 10.1111/1753-0407.13434. Epub 2023 Jun 13.
4
Why better interpretation of science leads to better care.为何对科学的更好解读能带来更好的医疗护理。
J R Soc Med. 2023 Apr;116(4):123. doi: 10.1177/01410768231169649.
High Blood Pressure and Cardiovascular Disease.高血压与心血管疾病。
Hypertension. 2020 Feb;75(2):285-292. doi: 10.1161/HYPERTENSIONAHA.119.14240. Epub 2019 Dec 23.
4
Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis.血压与老年人死亡率之间的关联是否因衰弱而不同?系统评价和荟萃分析。
Age Ageing. 2019 Sep 1;48(5):627-635. doi: 10.1093/ageing/afz072.
5
Intensive versus Usual Control of Hypertension in the Prevention of Cardiovascular and Renal Outcomes: A Cumulative Meta-Analysis of Randomized Controlled Trials.强化降压与常规降压对预防心肾血管结局的影响:一项随机对照试验的累积荟萃分析。
Kidney Blood Press Res. 2019;44(3):384-395. doi: 10.1159/000499009. Epub 2019 May 10.
6
2018 ESC/ESH Guidelines for the management of arterial hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南。
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
7
Hypertension treatment for older people-navigating between Scylla and Charybdis.老年人高血压治疗——在斯库拉和卡律布狄斯之间航行。
Age Ageing. 2018 Jul 1;47(4):505-508. doi: 10.1093/ageing/afy053.
8
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.2 型糖尿病及其并发症的全球病因学和流行病学。
Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8.
9
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2017美国心脏病学会/美国心脏协会/美国医师协会/美国心脏病学学会/美国预防医学学院/美国老年病学会/美国药学协会/美国血液学会/美国预防医学学会/美国医学协会/美国初级保健医师学会成人高血压预防、检测、评估和管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组报告
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13.
10
Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.收缩压降低与心血管疾病和死亡风险:系统评价和网络荟萃分析。
JAMA Cardiol. 2017 Jul 1;2(7):775-781. doi: 10.1001/jamacardio.2017.1421.